@article{8459e134bdf94ab190ef1da4b2283296,
title = "From TADS and SOFTADS to TORDIA and Beyond: What's new in the treatment of adolescent depression?",
abstract = "Major depressive disorder in adolescents is associated with significant morbidity and mortality. Major advances have been made in recent years in the treatment of adolescent depression, with promising outcomes. However, limitations of currently available treatments have prompted attempts to better understand pediatric depression from a broader perspective and to develop more effective treatment strategies in the future.",
keywords = "Adolescent, Cognitive-behavioral therapy, Depression, Pharmacotherapy",
author = "Yu, {Zheya Jenny} and Kratochvil, {Christopher J.} and Weller, {Ronald A.} and Mira Mooreville and Weller, {Elizabeth B.}",
note = "Funding Information: Disclosure Dr. Kratochvil receives grant support from Eli Lilly and Company, Abbott Laboratories, and Somerset Pharmaceuticals; serves as a consultant for Eli Lilly and Company, Abbott Laboratories, the Neuroscience Education Institute, MedAvante, AstraZeneca, and Pfizer; serves as editor of the Brown University Child & Adolescent Psychopharmacology Update and a member of the REACH Institute Primary Pediatric Psychopharmacology Steering Committee; and receives a study drug for an NIMH-funded study from Eli Lilly and Company and Abbott Laboratories.",
year = "2010",
month = apr,
doi = "10.1007/s11920-010-0094-x",
language = "English (US)",
volume = "12",
pages = "88--95",
journal = "Current psychiatry reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "2",
}